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Aim. To compare the effects of two therapeutic protocols for the patients with recurrent
miscarriages associated with the presence of antiphospholipid (anticardiolipin) antibodies.
Methods. A prospective observational study included 20 patients with antiphospholipid
antibodies in the first grooup who received low-molecular heparin and aspirin. The second
group of 20 patients, in addition to this therapy, received immunotherapy (intravenous im-
munoglobulin). Aspirin was administered at the time of a positive pregnancy test, and low-
molecular heparin not before the fetal heart activity registration by ultrasound. Intrave-
nous immunoglobulin was given prior to the conception or at the beginning of the preg-
nancy. We compared these groups according to the pregnancy outcomes and the occur-
rence of complications during pregnancy, using standard statistical tests. Results. The rate
of positive gestational outcome in the patiens treated with aspirin and low-molecular hepa-
rin was 85% (17/20), and in the second group it was 90% (18/20). There was no significant
difference in pregnancy outcomes between these groups (p  >  0.05), except for the oc-
curence of preeclampsia and thrombocytopenia, which were recorded only in the aspirin
and low-molecular heparin group, but with no statistical significance (p > 0.05) compared
to the second group, which received immunoglobulin additionally. Conclusion. There was
no significant difference (p > 0.05) in pregnancy outcomes between the two studied thera-
peutic protocols, but the therapy with aspirin and low-molecular heparin was cheaper and
easier to apply than the therapy with immunoglobulins. The results of our study confirmed
that the final pathogenic mechanisms in recurrent fetal miscarriages were inflammation
and thrombosis of the uteroplacental blood vessels.
K e y  w o r d s : antibodies,  antiphospholipid; abortion, spontaneous;
heparin, low-molecular-weight; aspirin;
immunoglobulins; pregnancy outcome.
Introduction
Antiphospholipid syndrome (APAS) is characterized by
the pressence of circulating autoantibodies against negatively
ionized phospholipids, which is clinically manifested by
thrombosis, thrombocytopenia, and recurrent miscarriages (1).
The incidence of recurrent spontaneous abortions in patients
with antiphospholipide antibodies (APA) may range up to
90%, of which 75% occures in the first trimester (2).
It is possible that the repeated abortions are caused by
the thrombotic events in the placental blood vessels, which
results in extensive infarctions causing placental insuffi-
ciency (2).
There are different therapeutic approaches to APAS
that include corticosteroids, immunotherapy, aspirin and
heparin (3). The effect of low-dose heparin in APA associ-
ated with reccurent fetal loss could cause the antithrombotic
activity of heparin which binds to the vessel walls, and thus
enhances the inactivation of thrombin and factor Xa in the
endothelium (4). Heparin also has the capacity to adsorb
antiphospholipid antibodies (APA) (4). Low-dose aspirin
has the antithrombotic and antiplateletantiaggregation ac-
tivities based on the inhibition of enzyme cyclooxygenase
and consequently the synthesis of thromboxane. Addition-
aly, aspirin stimulates the production of interleukin-3 that
helps the development of fetoplacental units (5). The com-Страна 436 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Број 6
bined treatment with aspirin and heparin is a reasonable and
well accepted therapeutic approach in pregnant women with
APAS (4, 5). In fact, this combination may promote a suc-
cessful embryonic implantation in the early stages of preg-
nancy, and protect against thrombosis of uteroplacental
blood vessels after a successful placentation (3−5).
Immunotherapy with intravenous gamma-globulin
(IVIG) has recently gained considerable attention in the lit-
erature (6−8). IVIG probably reacts with the receptors on
the macrophage surface, blocking the Fc receptors and in-
creasing the number of suppressor T cells (6, 7).
In addition, the therapy combined with immunosupre-
sives (high dose corticosteroides) and antiplatelet drugs
(low-dose heparin or aspirin) was associated with a variety
of complications during pregnancy (7, 8).
The aim of the study was to compare the effects of two
therapeutic protocols for the patients with recurrent mis-
cariages associated with the presence of antiphospholipid
antibodies.
Methods
Our study was conducted in the Institute of Gynecol-
ogy and Obstetrics of the Clinical Center of Serbia, from
1998 to 2002. It was a prospective clinical trial including 40
patients with recurrent fetal loss associated with the pres-
ence of antiphospholipid antibodies, and treated with aspirin
and heparin (n  =  20) in the first group, and aspirin, and
heparin and IVIG (n = 20) in the second group. Their main
characteristics are given in Table 1. The mean gestational
age of the patients in the first group (aspirin and heparin)
was 29.3 ± 2.5 weeks, while in the second, triple therapy
group, it was 30.2  ±  2.0 weeks. We compared the gesta-
tional age results between these two groups. Patients in-
cluded in this study had two or more consecutive sponta-
neus abortions, caused by the immune disorders. The aver-
age number of spontaneus abortions in the aspirin
and heparin group was 4.1 ± 1.6, while in the second, triple
therapy group, it was 4.6 ± 1.2. Antiphospholipid antibodies
were detected by an enzyme-linked immunosorbent assay
(ELISA). The IgG anticardiolipin level of ≥ 5U/L, and the
IgM anticardiolipin level of ≥ 3U/L were considered posi-
tive. In our study, aspirin was given in a dose of 100 mg
daily, after the pregnancy test was positive. Low-molecular
weight heparin was started when fetal heart activity was
registered by ultrasound, and it was given in a dose of 0.3
units subcutaneously at 12-hour intervals. The treatment
was interrupted in case of miscarriage, or at 34 weeks of
gestation. IVIG was given prior to the conception, or at the
beginning of pregnancy in a dose of 10 g once a month until
34 weeks of gestation.
Pregnancies were controlled by Doppler ultrasound,
and by biochemical measuring of the levels of antibodies.
According to the level of autoantibodies, patients were
devided into two groups, a group with a moderate, and a
group with a high antibody level, respectively.
Results
Eighteen patients in the aspirin and heparin group had
a moderate level of APA, while seventeen of the patients in
the triple therapy group had similar antibody level.
The differences in characteristics between the groups
were assessed by the Fisher's exact test for categorical vari-
able, and the Student's t-test for continous variable; a p-
value of 0.05 or less was considered statistically significant.
There was no significant difference  (p > 0.05) in the
mean gestational age nor in the average number of sponta-
neus abortions between the studied groups. There was sig-
nificant difference (p < 0.01) in the mean value of the IgG
anticardiolipins antibodies with higher level in the second,
triple therapy group (30.5 ± 4.2 U/L), compared to the aspi-
rin and heparin group (20.05 ± 4.1 U/L), which was the de-
cisive factor for the choice of the therapy protocol. There
was no significant difference (p > 0.05) between mean val-
ues of IgM anticardiolipin antibodies in the groups, (the
first,  aspirin and heparin  group:  10.05 ± 2.2  U/L,  vs.  the
second, triple therapy group: 11.06 ± 1.8 U/L).
Table 1.
Characteristics of patients included in the study
Characteristics of patients Heparin + Aspirin Heparin + Aspirin
+  IVIG
Gestational success 17/20 (85%) 18/20 (90%)
Preterm birth (before 37 g.w.) 4/20 (20%) 2/20 (10%)
Average gestational age 36.05 ± 1.68 37.l5 ± 1.05
Median birthweight  of infants   2 253 ± 1 145 2 718 ± 589
Preeclampsia 3/20 (15%) 0/20
Intrauterine growth restriction 3/20 (15%) 2/20 (10%)
Thrombocytopenia (tr <50 000) 3/20 (15%) 0/20
Premature labour  with rupture of membrans 2/20 (10%) 2/20 (10%)
Apgar score at 5 min < 7 7/20 (35%) 5/20 (25%)
Cesarean delivery 9/20 (45%) 11/20 (55%)Број 6 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Страна 437
Gestational success reached 85% (17/20) in the aspi-
rin- and heparin-group, and the rate of success in the second
group treated with heparin, aspirin and IVIG was 90%
(18/20). There was no statistical significance (χ
2 = 0.02855
p  >  0.05) in pregnancy outcome between the two studied
therapeutic protocols. Three pregnancies (15%) terminated
with a miscarriage in the aspirin and heparin group, mainly
in the first trimester of pregnancy, and the two women
(10%) from the second group had spontaneous abortion
within this study. One woman (5%) from the aspi-
rin and heparin group had a stillbirth.
Two patients (10%) per each group had premature la-
bor with rupture of membranes. Pregnancy induced hyper-
tension and thrombocytopenia (tr < 50 000/L) complicated
15% (3/20) of the pregnancies, and antepartal hemorrhage
5% (1/20) in the aspirin and heparin group. The average
gestational age at the delivery was 36.05 ± 1.68 weeks in
the aspirin and heparin group, while in the second group it
was 37.15  ±  1.05 weeks. There was no significant differ-
ence in the gestational age at the delivery between the
studied groups (t 0.25 p > 0.05). Twenty percent (4/20) in
the first group and 10% of the babies (2/20) in the second
group were born before 37 weeks of gestation. The median
birthweight of the infants in the aspirin and heparin group
was 2 253 ± 1 145 g, respectively, while the median birth
weight was 2 718 ± 589 g in the triple therapy group. How-
ever, 15% (3/20) of the infants were small for their gesta-
tional age (intrauterine growth restriction) in the first group,
and 10% (2/20) in the second, triple therapy group. There
was no significant difference in the average birthweight
between the groups (t=1.6 p > 0.05). In each case of neona-
tal birth weight above the 10
th centile growth curve, the
uterine artery Doppler tracing demonstrated the abnormal
blood velocity waveforms, indicating placental insuffi-
ciency. Apgar score at 5 min  <  7 was recorded in 35%
(7/20) of the patients in the heparin and aspirin group, while
in the women with triple therapy in 25% (5/20). In the aspi-
rin  and  heparin group, cesarean delivery was performed
beacuse of the signs of fetal distress in six cases, and in
three cases the indication for cesarean delivery was mater-
nal hypertension. In the second group, cesarean delivery
was performed in the eleven cases.
Discussion
Pregnancy outcome in women with spontaneus abor-
tion associated with antiphospholipid antibodies, was en-
hanced by the various treatments causing variable side-
effects (7, 8). Final pathogenic mechanisms in APAS lead-
ing to the abortion were inflammation and thrombosis, and
it could be prevented by the antithrombotic and antiinflam-
matory activities of heparin and aspirin (8). Two recent
publications have demonstrated that the combination of
heparin and aspirin was more effective than aspirin alone in
pregnancies with the previous fetal loss associated with
APA (8, 9). In one of them, the gestational results in the
group of 25 women treated with aspirin and heparin were
compared with the results of the group of 25 women who
were given only aspirin (9). Gestational success was 80% in
the first group, and only 44% in the aspirin only group (9).
These results suggested that heparin played the major
role in the prevention of the recurrent fetal loss, yet the
complete mechanism of action of this drug was still un-
known (10). Except for its main effect, heparin has the ca-
pacity to adsorb ASA (10). Phosphatidylserine and phos-
phatidylethanolamine are the phospholipids that participate
as the adhesion molecules in the fusion of syncytiotropho-
blast, therefore, antiphospholipid antibodies could cause
abortion, so heparin could inhibit that effect (11). Accord-
ingly, heparin has been used in trying to improve the im-
plantation of in vitro fertilization programs (12). Sher et al.
(13, 14) reported significant difference in the number of vi-
able pragnancies among the infertile patients with APAS
treated with heparin and aspirin, compared with the control
group.
Our experience with the combined treatment with aspi-
rin and heparin also confirmed a high live-birth rate among
the women with recurrent fetal loss and APAS (14). At the
University of Utah (15), approximately onethird of APAS
pregnancies resulted in live births and the deliveries prior to
34 weeks' gestation, which was also recorded in our study,
in which only 20% of all the pregnancies was delivered
preterm. Our findings that most miscarriages (12.5% preg-
nancies) occured in the first trimester confirmed the previ-
ous prospective observational study (15).
Despite the increased rates of live birth, the pregnant
women treated with heparin and aspirin had some obstetric
complications (preeclampsia, intrauterine growth restriction,
preterm birth) (16). These complications have prompted a
search for the better therapy. The treatment with IVIG was
confirmed as promising in a small number of cases refrac-
tory to heparin and prednisone (17). Obstetric complica-
tions, such as preeclampsia and thrombocytopenia, occurred
rarely in patients treated with IVIG, and the reason for that
could be their immunological origin (18). A high dose of
intravenous immunoglobulin therapy appeared to inhibit
anticoagulant antibodies in pregnant and non-pregnant
women by suppressing the autoantibody production (19).
Since the efficacy of IVIG has not been proven yet in the
appropriately designed studies, and the drug is extremely
expensive, it has still not been recommended as the com-
mon therapy (19).
 In our study, two pregnancies (10%) were lost in the
triple therapy group, and three (15%) in the aspi-
rin  and  heparin group, providing evidence that abnormal
placentation could not be avoided in spite of the optimal
treatment (aspirin, heparin, immunoglobulin). In fact, these
patients had the highly positive level of autoantibodies, and
their live-birth rate was lower, than in the patients with
moderate APA level. However, the therapy was useful in
treating the cases with the moderate level of autoantibodies
(eighteen patients from the heparin and aspirin group, andСтрана 438 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Број 6
seventeen patients from the triple terapy group), so that the
distinction between the two groups was justified. According
to recent publications, some authors suggested the initiation
of the therapy with aspirin and heparin prior to the concep-
tion in women with recurrent pregnancy loss, so that the
problem in early gestations could be avoided (20−22).
Also, there were suggestions that in some cases (idio-
pathic thrombocytopenia and preeclampsia) the use of im-
munotherapy was favorable (19). Successful pregnancy out-
comes in the women with APAS in our study, treated with
heparin and aspirin, confirmed the findings that the mecha-
nisms in pathogenesis of recurrent fetal loss included
thrombosis and inflammation of the uteroplacental blood
vessels (23).
Conclusion
In the women with recurrent miscarriages associated
with the presence of antiphospholipid antibodies, the ther-
apy with aspirin and heparin was effective, cheaper (which
is important for the developing countries), and easier to
provide than the therapy which included intravenous immu-
noglobulins. A close antenatal surveillance and the planned
delivery of these pregnancies were necessary for achieving
the positive perinatal results. On the other hand, the results
of this study suggested that the inflammation and thrombo-
sis of the uteroplacental blood vessels were included in the
pathogenesis of recurrent pregnancy loss in women with
APAS.
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POREĐENJE DVA TERAPIJSKA PROTOKOLA KOD BOLESNICA SA
ANTIFOSFOLIPIDNIM ANTITELIMA I HABITUALNIM POBAČAJIMA
Cilj. Cilj ove studije bio je poređenje efikasnosti dva terapijska protokola u lečenju
bolesnica sa habitualnim pobačajima i prisustvom antifosfolipidnih antikardiolipin-
skih antitela. Metod. Prospektivnom opservacijskom studijom obuhvaćeno je 40
bolesnica sa prisutnim antifosfolipidnim antitelima od kojih je njih 20 u prvoj grupi
dobijalo aspirin i niskomolekulski heparin, a drugih 20 ispitanica je pored ove tera-
pije dobijalo i imunoglobuline. Aspirin je dat kada je ustanovljena trudnoća, dok se
niskomolekulski heparin davao nakon ultrazvučno registrovane srčane aktivnosti
ploda. Imunoglobulini su dati ili pre začeća ili na početku trudnoće. Efikasnost pri-
menjene terapije procenjivana je na osnovu ishoda trudnoća, kao i komplikacija u
toku trudnoće. Za procenu efikasnosti korišćeni su standardni statistički testovi.
Rezultati. Pozitivan perinatalni ishod u prvoj grupi (aspirin i heparin) ustanovljen je
kog 85% bolesnica, dok je u drugoj grupi bio 90%, što nije bilo statistički značajno
(p > 0,05). Preeklampsija i trombocitopenija su se kao komplikacije javile samo u
grupi trudnica koje su dobijale asprin i niskomolekulski heparin, bez statistički zna-
čajne razlike (p > 0,05) u odnosu na grupu koja je pored ove terapije dobijala i imu-
noglobuline. Zaključak. S obzirom na to da je uspešan perinatalni ishod bio podje-
dnako zastupljen u obe ispitivane grupe, kod bolesnica sa prisutnim antifosfolipid-
nim antitelima i habitualnim pobačajima može se preporučiti primena aspirina i nis-
komolekulskog heparina, tim pre što je ova terapija jednostavnija za primenu i jefti-
nija od terapije koja uključuje i primenu imunoglobulina. Osim toga, naši rezultati
potvrđuju da je mehanizam ovih poremećaja baziran na inflamaciji i trombozi krvnih
sudova placente.
Kl juč ne reč i : antitela, antifosfolipidna; abortus; heparin,
niskomolekulski; aspirin; imunoglobulini; trudnoća,
ishod.
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